IV morphine patient-controlled analgesia

Preclinical

IV morphine patient-controlled analgesia is one of 3 therapeutic programs targeting Postoperative Pain, Acute. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Postoperative Pain, AcuteRecruiting

Postoperative Pain, AcutePreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Postoperative Pain, Acute

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

1 2

Tylenol

KKenvue Brands

Phase 3

1 3

IV morphine patient-controlled analgesia

OOndokuz Mayıs University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Postoperative Pain, Acute

NCT07164677

Clinical

Trials by Indication[1]

Postoperative Pain, Acute1 trial

Efficacy of the Serratus Posterior Superior Intercostal Plane Block for Postoperative Acute Pain Management in Open-Heart Surgery

Recruiting·OOndokuz Mayıs University·Preclinical·NCT07164677·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IV morphine patient-controlled analgesia. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for IV morphine patient-controlled analgesia. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ondokuz Mayıs University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: OOndokuz Mayıs University

IV morphine patient-controlled analgesia

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Postoperative Pain, Acute1 trial

References

Drug Info

Quick Facts

Related News